Bio View

Bio View FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bio View (BIOV.TA) as of Oct 19, 2026 is 20.28 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 99.78 % — a change of -79.67% (lower).

FCF Conversion

20.28 %

YoY

-79.67%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bio View is 2025 20.28 % . FCF Conversion Rate (FCF/EBITDA) of Bio View was 2024 99.78 % . It decreases by -79.67% lower compared to the previous year.

The Bio View FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
81.18 ILS
Jan 1, 2019
90.61 ILS
Jan 1, 2020
56.33 ILS
Jan 1, 2021
118.50 ILS
Jan 1, 2022
87.05 ILS
Jan 1, 2023
-31.59 ILS
Jan 1, 2024
99.78 ILS
Jan 1, 2025
20.28 ILS
The Bio View FCF Conversion history
YEARFCF ConversionYoY
20.28 %-79.67%
99.78 %-415.83%
-31.59 %-136.29%
87.05 %-26.54%
118.50 %+110.35%
56.33 %-37.83%
90.61 %+11.63%
81.18 %+586.70%
11.82 %-85.46%
81.32 %-25.73%
109.49 %-27.10%
150.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bio View Stock analysis

What does Bio View do? Bio View Ltd, based in Rehovot, Israel, operates in the Health Care sector, specializing in the research, development, marketing, and sales of advanced imaging systems. The company manufactures and services the Duet workstation, an automated cell diagnostic system used in cytology, hematology, and pathology laboratories for detecting and analyzing abnormal cells. It also offers the ALLEGRO and ACCORD workstations for specialized applications in cancer diagnosis, minimal-residual disease monitoring, and FISH-based analyses in cytogenetics and oncology. Bio View is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio View stock

FCF Conversion Rate (FCF/EBITDA) of Bio View is 20.28 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Bio View changed from 99.78 % to 20.28 %, representing a -79.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bio View since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bio View with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Bio View

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Bio View